Organisation paid for research Program year 2023 Source: CMS Open Payments

Wolfe Clinic

Neither a doctor nor a teaching hospital

Research payments

$2,037,120

95 payments

Through program year 2023, Wolfe Clinic is reported as receiving $2,037,120 in research payments, across 95 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$3,330	1
2022	Research	$24,708	2
2021	Research	$646,108	29
2020	Research	$901,392	27
2019	Research	$461,582	36

Breakdown

Who paid Research payments · program years 2019–2023

Genentech, Inc. $1,308,948 85 payments
Novartis Pharmaceuticals Corporation $728,172 10 payments

Studies the money was for Research payments · program years 2019–2023

Va2 Phiii $609,590 16 payments
A Multicenter Randomized Double Masked Phase 3A Study to Assess Safety and Efficacy of Brolucizumab 6 MG Q4 Weeks Compared to Aflibercept 2 MG Q4 Weeks in Patients With Neovascular Age Related MacUlar Degeneration Namd With Persistent Retinal Fluid $580,425 4 payments
Port Delivery System for Ranibizumab $235,251 20 payments
Va2 Phiii Yosemite $183,912 13 payments
Phase 2 of Ro7171009 in Ga $95,080 5 payments
A 64-Week, Phase 3B, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6Mg Compared to Aflibercept 2Mg in A Treat to Control Regimen in Patients With Neovascular Age-Related MacUlar Degeneration $80,780 4 payments
A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $66,967 2 payments
Port Delivery System of Ranizibumab Extension Study $53,143 10 payments
Open Label Extension Study to Evaluate the Long Term Safety of Faricimab in Patients With Namd $44,386 6 payments
Port Delivery System of Ranibizumab Extension Study $43,957 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.